The acquisition would include $85 million at closing and up to an additional $165 million in growth-based earnout payments over the next four years, Conmed said in a news release.
The BioBrace implant is an FDA-cleared bioinductive scaffold designed to reinforce soft tissue where weakness exists and facilitate healing, according to Biorez.
The transaction is expected to close this month.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
